Lunit

Overview

Lunit develops medical AI software designed to transform cancer care through earlier detection and precision oncology. Their solutions leverage artificial intelligence to analyze complex clinical data, providing actionable insights for healthcare professionals across various stages of cancer management. The company aims to improve patient outcomes by enhancing the accuracy and efficiency of cancer screening and treatment decisions.

Key Features

• Lunit INSIGHT MMG (2D) — AI software for improved detection of breast cancer in 2D mammography.
• Lunit INSIGHT DBT (3D) — AI software designed to assist in the detection of breast cancer in 3D digital breast tomosynthesis.
• Lunit INSIGHT CXR — AI software for analyzing chest X-rays to detect abnormalities.
• Lunit SCOPE IO - TME Analysis — AI-powered analysis of the tumor microenvironment for precision oncology.
• Lunit SCOPE IHC Suite — AI solutions for quantifying immunohistochemistry (IHC) markers.
• Lunit SCOPE GP - Genotype Prediction — AI for predicting genotypes from image analysis to inform treatment strategies.

Who It's For

Lunit's solutions are designed for radiologists, oncologists, and other healthcare professionals involved in cancer screening, diagnosis, and treatment planning. Their products also cater to biopharmaceutical companies seeking to accelerate oncology innovation through AI-driven biomarker analysis and companion diagnostics for clinical trials. The software is utilized in clinical settings globally, serving hospitals and research institutions.

Notable Strengths

Lunit demonstrates significant global adoption, with its medical AI software deployed in over 10,000 customer sites across more than 65 countries. The company emphasizes clinical validation and regulatory approvals, with Lunit INSIGHT MMG and Lunit INSIGHT DBT being FDA-cleared. Their platform offers a modular and interoperable ecosystem, facilitating seamless integration into existing healthcare workflows and supporting a broad spectrum of cancer care stages from screening to precision oncology.